Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma

May 2nd 2024

A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.

Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Dr Eroglu on Ceritinib With or Without Trametinib in Pretreated Advanced Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma

May 1st 2024

Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Dr Eroglu on the Safety Profile of Ceritinib Plus Trametinib in Advanced Melanoma

April 25th 2024

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma

April 23rd 2024

OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.

Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma

April 23rd 2024

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Uveal Melanoma Immunogenomic Score Shows Predictive Potential

April 23rd 2024

Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.

Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC

April 22nd 2024

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

April 22nd 2024

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel

April 19th 2024

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

April 18th 2024

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma

April 18th 2024

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Dr Hamid on the Use of Lifileucel in Advanced Melanoma

April 16th 2024

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

April 10th 2024

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti–PD-1 Therapy in High-Risk Resectable Melanoma

April 9th 2024

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

April 8th 2024

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.